EA202191758A1 - Пептиды для лечения и профилактики диабета и связанных с ним заболеваний - Google Patents

Пептиды для лечения и профилактики диабета и связанных с ним заболеваний

Info

Publication number
EA202191758A1
EA202191758A1 EA202191758A EA202191758A EA202191758A1 EA 202191758 A1 EA202191758 A1 EA 202191758A1 EA 202191758 A EA202191758 A EA 202191758A EA 202191758 A EA202191758 A EA 202191758A EA 202191758 A1 EA202191758 A1 EA 202191758A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
peptides
treatment
related diseases
prevention
Prior art date
Application number
EA202191758A
Other languages
English (en)
Inventor
Венсан Марион
Original Assignee
Юниверсите Де Страсбур
Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юниверсите Де Страсбур, Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) filed Critical Юниверсите Де Страсбур
Publication of EA202191758A1 publication Critical patent/EA202191758A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11013—Protein kinase C (2.7.11.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Abstract

Настоящее изобретение касается пептидов для лечения диабета и связанных с ним заболеваний.
EA202191758A 2018-12-21 2019-12-20 Пептиды для лечения и профилактики диабета и связанных с ним заболеваний EA202191758A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306794 2018-12-21
PCT/EP2019/086573 WO2020127904A1 (en) 2018-12-21 2019-12-20 Peptides for treatment and prevention of diabetes and associated disorders

Publications (1)

Publication Number Publication Date
EA202191758A1 true EA202191758A1 (ru) 2021-10-01

Family

ID=65200524

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191758A EA202191758A1 (ru) 2018-12-21 2019-12-20 Пептиды для лечения и профилактики диабета и связанных с ним заболеваний

Country Status (25)

Country Link
US (1) US20220133860A1 (ru)
EP (2) EP4233890A3 (ru)
JP (2) JP7335337B2 (ru)
KR (2) KR102555817B1 (ru)
CN (2) CN113301916B (ru)
AU (1) AU2019408382A1 (ru)
BR (1) BR112021012134A2 (ru)
CA (1) CA3124260C (ru)
CY (1) CY1126054T1 (ru)
DK (1) DK3897697T3 (ru)
EA (1) EA202191758A1 (ru)
ES (1) ES2948264T3 (ru)
FI (1) FI3897697T3 (ru)
HR (1) HRP20230591T1 (ru)
HU (1) HUE062537T2 (ru)
IL (1) IL284029B2 (ru)
LT (1) LT3897697T (ru)
MX (1) MX2021007460A (ru)
PL (1) PL3897697T3 (ru)
PT (1) PT3897697T (ru)
RS (1) RS64265B1 (ru)
SG (1) SG11202107923WA (ru)
SI (1) SI3897697T1 (ru)
WO (1) WO2020127904A1 (ru)
ZA (1) ZA202105101B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022098051A1 (ko) 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
WO2023214802A1 (ko) 2022-05-03 2023-11-09 한국생명공학연구원 신규 펩타이드 및 이의 항염 및 재생 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2343934A1 (en) * 1998-09-25 2000-04-06 The Children's Medical Center Corporation Short peptides which selectively modulate the activity of protein kinases
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
PE20050157A1 (es) 2003-05-20 2005-05-17 Novartis Ag Derivados de n-acil nitrogeno heterociclicos como ligandos del receptor activador del proliferador de peroxisoma (ppar)
EP1768650B1 (en) 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
EP1843746B1 (en) 2005-01-14 2011-03-16 Camurus Ab Somatostatin analogue formulations
ATE540971T1 (de) * 2005-06-29 2012-01-15 Hadasit Med Res Service Proteinkinase-c-inhibitoren zur prävention von insulinresistenz und typ-2-diabetes
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
EP2334317B1 (en) 2008-09-16 2017-06-14 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
CA2937447A1 (en) * 2014-01-29 2015-08-06 Vaxine Pty Ltd New target for diabetes treatment and prevention.
EP3421485A1 (en) * 2017-06-30 2019-01-02 Université de Strasbourg Peptides for treatment and prevention of hyperglycaemia
JP7362611B2 (ja) * 2017-12-14 2023-10-17 ユニヴェルシテ・ドゥ・ストラスブール 非アルコール性脂肪肝疾患及び線維症の治療及び予防のためのペプチド
JP2021512051A (ja) * 2018-01-23 2021-05-13 ギラ セラピューティクス インコーポレイテッドＧｉｌａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ペプチドｙｙ薬学的調剤物、組成物、および方法

Also Published As

Publication number Publication date
DK3897697T3 (da) 2023-06-26
EP4233890A2 (en) 2023-08-30
CN113301916A (zh) 2021-08-24
ZA202105101B (en) 2023-10-25
IL284029A (en) 2021-08-31
JP7335337B2 (ja) 2023-08-29
SI3897697T1 (sl) 2023-10-30
CA3124260C (en) 2023-01-03
EP3897697B1 (en) 2023-03-29
EP3897697A1 (en) 2021-10-27
MX2021007460A (es) 2022-11-15
ES2948264T3 (es) 2023-09-07
KR20210106520A (ko) 2021-08-30
KR20230110659A (ko) 2023-07-24
US20220133860A1 (en) 2022-05-05
FI3897697T3 (fi) 2023-06-21
IL284029B1 (en) 2023-05-01
AU2019408382A1 (en) 2021-08-12
PT3897697T (pt) 2023-06-27
CY1126054T1 (el) 2023-11-15
JP2023159268A (ja) 2023-10-31
SG11202107923WA (en) 2021-08-30
IL284029B2 (en) 2023-09-01
KR102555817B1 (ko) 2023-07-13
CN116196399A (zh) 2023-06-02
JP2022516012A (ja) 2022-02-24
CA3124260A1 (en) 2020-06-25
CN113301916B (zh) 2023-01-03
HUE062537T2 (hu) 2023-11-28
EP4233890A3 (en) 2023-10-11
LT3897697T (lt) 2023-07-10
BR112021012134A2 (pt) 2021-09-08
WO2020127904A1 (en) 2020-06-25
HRP20230591T1 (hr) 2023-09-15
PL3897697T3 (pl) 2023-07-24
RS64265B1 (sr) 2023-07-31

Similar Documents

Publication Publication Date Title
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201791775A1 (ru) Цистеиновая протеаза
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791773A1 (ru) Цистеиновая протеаза
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891399A1 (ru) Бипиразолильные производные, пригодные для лечения аутоиммунных заболеваний
BR112021024236A2 (pt) Proteínas multiespecíficas
MX2020007527A (es) Tratamiento de enfermedades oftalmologicas.
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EA202191476A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
EA202091521A1 (ru) ВАРИАНТЫ ДОМЕНА Fc IgG ЧЕЛОВЕКА С УЛУЧШЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CY1126054T1 (el) Πεπτιδια για θεραπεια και αποτροπη διαβητη και συναφων διαταραχων
EA201990988A1 (ru) Антитела против chikv и пути их применения
EA201792610A1 (ru) Способ лечения неврологического заболевания
EA201790336A1 (ru) Антитела к ангиопоэтинподобному белку 4 и способы применения
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение